Director at Dyne Therapeutics
Lubner serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition to Dyne’s Board of Directors, he previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019. Lubner is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.